File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1158/1535-7163.MCT-08-0326
- Scopus: eid_2-s2.0-51049118824
- WOS: WOS:000257964100047
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor γ ligand-induced growth inhibition in colon cancer
Title | Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor γ ligand-induced growth inhibition in colon cancer |
---|---|
Authors | |
Issue Date | 2008 |
Publisher | American Association for Cancer Research. The Journal's web site is located at http://mct.aacrjournals.org/ |
Citation | Molecular Cancer Therapeutics, 2008, v. 7 n. 7, p. 2203-2211 How to Cite? |
Abstract | We found previously that X-linked inhibitor of apoptosis protein (XIAP), a potent endogenous inhibitor of apoptosis, is overexpressed in colon cancer. Ligand-induced activation of peroxisome proliferator-activated receptor γ (PPARγ) has been shown to exert proapoptotic and antiproliferative effects in many cancer cell types. However, neither XIAP down-regulation alone nor monotherapy using PPARγ ligands is potent enough to control colon cancer. We explored whether XIAP inhibition and PPARγ activation offer a synergistic anticancer effect in colon cancer. HCT116-XIAP +/+ and HCT116-XIAP -/- cells were treated with troglitazone or 15-deoxy-Δ 12,14-prostaglandin J 2 (15-PGJ 2). Cell growth and apoptosis were measured. Nude mice were s.c. inoculated with HCT116 cells with or without oral troglitazone. Tumor growth, angiogenesis, and apoptosis were measured. Troglitazone- and 15-PGJ 2-induced growth inhibition and apoptosis were more prominent in HCT116-XIAP -/- cells. Troglitazone- and 15-PGJ 2-induced apoptosis correlated with enhanced cleavage of caspases and poly(ADPribose) polymerase, which were more profound in HCT116-XIAP -/- cells. Pretreatment of cells with XIAP inhibitor 1396-12 also sensitized HCT116-XIAP +/+ cells to PPARγ ligand-induced apoptosis. Troglitazone significantly retarded the growth of xenograft tumors, more significantly so in HCT116-XIAP -/- cell-derived tumors. Reduction of tumor size was associated with reduced expression of Ki-67, vascular endothelial growth factor, and CD31 as well as increased apoptosis. Loss of XIAP significantly sensitized colorectal cancer cells to PPARγ ligand-induced apoptosis and inhibition of cell proliferation. Thus, simultaneous inhibition of XIAP and activation of PPARγ may have a synergistic antitumor effect against colon cancer. Copyright © 2008 American Association for Cancer Research. |
Persistent Identifier | http://hdl.handle.net/10722/163200 |
ISSN | 2023 Impact Factor: 5.3 2023 SCImago Journal Rankings: 2.270 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Qiao, L | en_US |
dc.contributor.author | Dai, Y | en_US |
dc.contributor.author | Gu, Q | en_US |
dc.contributor.author | Kwok, WC | en_US |
dc.contributor.author | Zou, B | en_US |
dc.contributor.author | Ma, J | en_US |
dc.contributor.author | Wang, J | en_US |
dc.contributor.author | Lan, HY | en_US |
dc.contributor.author | Wong, BCY | en_US |
dc.date.accessioned | 2012-09-05T05:28:41Z | - |
dc.date.available | 2012-09-05T05:28:41Z | - |
dc.date.issued | 2008 | en_US |
dc.identifier.citation | Molecular Cancer Therapeutics, 2008, v. 7 n. 7, p. 2203-2211 | en_US |
dc.identifier.issn | 1535-7163 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163200 | - |
dc.description.abstract | We found previously that X-linked inhibitor of apoptosis protein (XIAP), a potent endogenous inhibitor of apoptosis, is overexpressed in colon cancer. Ligand-induced activation of peroxisome proliferator-activated receptor γ (PPARγ) has been shown to exert proapoptotic and antiproliferative effects in many cancer cell types. However, neither XIAP down-regulation alone nor monotherapy using PPARγ ligands is potent enough to control colon cancer. We explored whether XIAP inhibition and PPARγ activation offer a synergistic anticancer effect in colon cancer. HCT116-XIAP +/+ and HCT116-XIAP -/- cells were treated with troglitazone or 15-deoxy-Δ 12,14-prostaglandin J 2 (15-PGJ 2). Cell growth and apoptosis were measured. Nude mice were s.c. inoculated with HCT116 cells with or without oral troglitazone. Tumor growth, angiogenesis, and apoptosis were measured. Troglitazone- and 15-PGJ 2-induced growth inhibition and apoptosis were more prominent in HCT116-XIAP -/- cells. Troglitazone- and 15-PGJ 2-induced apoptosis correlated with enhanced cleavage of caspases and poly(ADPribose) polymerase, which were more profound in HCT116-XIAP -/- cells. Pretreatment of cells with XIAP inhibitor 1396-12 also sensitized HCT116-XIAP +/+ cells to PPARγ ligand-induced apoptosis. Troglitazone significantly retarded the growth of xenograft tumors, more significantly so in HCT116-XIAP -/- cell-derived tumors. Reduction of tumor size was associated with reduced expression of Ki-67, vascular endothelial growth factor, and CD31 as well as increased apoptosis. Loss of XIAP significantly sensitized colorectal cancer cells to PPARγ ligand-induced apoptosis and inhibition of cell proliferation. Thus, simultaneous inhibition of XIAP and activation of PPARγ may have a synergistic antitumor effect against colon cancer. Copyright © 2008 American Association for Cancer Research. | en_US |
dc.language | eng | en_US |
dc.publisher | American Association for Cancer Research. The Journal's web site is located at http://mct.aacrjournals.org/ | en_US |
dc.relation.ispartof | Molecular Cancer Therapeutics | en_US |
dc.title | Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor γ ligand-induced growth inhibition in colon cancer | en_US |
dc.type | Article | en_US |
dc.identifier.email | Qiao, L:lq8688@hotmail.com | en_US |
dc.identifier.email | Wang, J:jidewang@gmail.com | en_US |
dc.identifier.email | Wong, BCY:bcywong@hku.hk | en_US |
dc.identifier.authority | Qiao, L=rp00513 | en_US |
dc.identifier.authority | Wang, J=rp00491 | en_US |
dc.identifier.authority | Wong, BCY=rp00429 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1158/1535-7163.MCT-08-0326 | en_US |
dc.identifier.scopus | eid_2-s2.0-51049118824 | en_US |
dc.identifier.hkuros | 143050 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-51049118824&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 7 | en_US |
dc.identifier.issue | 7 | en_US |
dc.identifier.spage | 2203 | en_US |
dc.identifier.epage | 2211 | en_US |
dc.identifier.isi | WOS:000257964100047 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Qiao, L=7202151719 | en_US |
dc.identifier.scopusauthorid | Dai, Y=7401512993 | en_US |
dc.identifier.scopusauthorid | Gu, Q=24469982400 | en_US |
dc.identifier.scopusauthorid | Kwok, WC=24171150800 | en_US |
dc.identifier.scopusauthorid | Zou, B=35228257300 | en_US |
dc.identifier.scopusauthorid | Ma, J=35275386200 | en_US |
dc.identifier.scopusauthorid | Wang, J=35309087500 | en_US |
dc.identifier.scopusauthorid | Lan, HY=7102710832 | en_US |
dc.identifier.scopusauthorid | Wong, BCY=7402023340 | en_US |
dc.identifier.issnl | 1535-7163 | - |